TapewireFind a company

person · Reporting owner

Rootsaert Rodney Gerard

Disclosed activity across 1 company

Tapewire entity
57268
SEC CIK
0001577894

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
VOLITIONRX LTDVNRX · Entity 8241SecretaryMarch 17, 2026March 19, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

VOLITIONRX LTD

Report date March 17, 2026 · Filed March 19, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect273,993 Reported balance After 2026-03-17 transaction · row 1
1 source row

Row 1 · 2026-03-17 · Tax withholding · Disposed 3,948 · Balance 273,993

F1: Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the reporting person upon settlement of 9,400 restricted stock units. No shares were sold by the reporting person or VolitionRx in such transaction.

Common StockSEC Table I · non-derivativeIndirectBy Concord International, Inc.1,007,718 Reported balance Holding disclosure · report date 2026-03-17 · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · Balance 1,007,718

F2: The shares of common stock are held directly by Concord International, Inc. The reporting person is a controlling director of Concord International, Inc. and shares voting and dispositive control over the shares of common stock held by Concord International, Inc.

Filing footnotes · ownership attribution and instrument terms

F1: Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the reporting person upon settlement of 9,400 restricted stock units. No shares were sold by the reporting person or VolitionRx in such transaction.

F2: The shares of common stock are held directly by Concord International, Inc. The reporting person is a controlling director of Concord International, Inc. and shares voting and dispositive control over the shares of common stock held by Concord International, Inc.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
March 17, 2026 Filed Mar 19, 2026 20:30 UTC VOLITIONRX LTD VNRX · Entity 8241 Tax withholdingCommon Stock 3,948 $0.19 $750.12
Disclosure

SEC source: 0001477932-26-001490 · form4.xml · nonDerivative · entry 1

Rootsaert Rodney Gerard · CIK 0001577894 · Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 273,993

F1 · shares: Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the reporting person upon settlement of 9,400 restricted stock units. No shares were sold by the reporting person or VolitionRx in such transaction.

Read SEC document
March 01, 2026 Filed Mar 3, 2026 21:31 UTC VOLITIONRX LTD VNRX · Entity 8241 Tax withholdingCommon Stock 3,321 $0.21 $707.37
Disclosure

SEC source: 0001477932-26-001147 · form4.xml · nonDerivative · entry 1

Rootsaert Rodney Gerard · CIK 0001577894 · Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 277,941

F1 · shares: Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the reporting person upon settlement of 7,908 restricted stock units that were awarded in lieu of cash compensation that would otherwise have been owed to the reporting person. No shares were sold by the reporting person or VolitionRx in such transaction.

Read SEC document
February 26, 2026 Filed Feb 27, 2026 21:31 UTC VOLITIONRX LTD VNRX · Entity 8241 GrantCommon Stock 119,000 $0.00 $0.00
Disclosure

SEC source: 0001477932-26-001100 · form4.xml · nonDerivative · entry 1

Rootsaert Rodney Gerard · CIK 0001577894 · Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 281,262

F1 · shares: On February 26, 2026, the reporting person was awarded 119,000 restricted stock units ("RSUs") under the Issuer's 2024 Stock Incentive Plan in lieu of cash compensation that would otherwise have been owed to the reporting person. The RSUs will be earned in twelve approximately equal monthly installments commencing on March 1, 2026. Once earned, they will remain subject to additional time-based vesting in a single installment on February 26, 2027, and are generally subject to continued service by the reporting person throughout each applicable earning and vesting date. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have been earned and vested as of the vesting date.

Read SEC document
February 01, 2026 Filed Feb 3, 2026 21:05 UTC VOLITIONRX LTD VNRX · Entity 8241 Tax withholdingCommon Stock 3,196 $0.29 $910.86
Disclosure

SEC source: 0001477932-26-000606 · form4.xml · nonDerivative · entry 1

Rootsaert Rodney Gerard · CIK 0001577894 · Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 162,262

F1 · shares: Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the reporting person upon settlement of 7,611 restricted stock units that were awarded in lieu of cash compensation that would otherwise have been owed to the reporting person. No shares were sold by the reporting person or VolitionRx in such transaction.

Read SEC document
January 22, 2026 Filed Jan 23, 2026 21:06 UTC VOLITIONRX LTD VNRX · Entity 8241 GrantCommon Stock 28,200 $0.00 $0.00
Disclosure

SEC source: 0001477932-26-000363 · form4.xml · nonDerivative · entry 1

Rootsaert Rodney Gerard · CIK 0001577894 · Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 165,458

F1 · shares: On March 17, 2025, the reporting person was awarded 94,000 restricted stock units ("RSUs") under the Issuer's 2024 Stock Incentive Plan, subject to vesting upon the achievement of certain corporate performance goals on or prior to June 30, 2025 and December 31, 2025 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 28,200 RSUs vesting. The RSUs are further subject to a 3-year time-based vesting schedule, vesting in three equal installments of 9,400 units on each of March 17, 2026, 2027 and 2028, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested. The rights with respect to the remaining 65,800 RSUs did not vest and were cancelled on June 30, 2025 and January 22, 2026, respectively.

Read SEC document
November 01, 2025 Filed Nov 4, 2025 21:01 UTC VOLITIONRX LTD VNRX · Entity 8241 Tax withholdingCommon Stock 3,197 $0.43 $1,387.50
Disclosure

SEC source: 0001477932-25-007900 · form4.xml · nonDerivative · entry 1

Rootsaert Rodney Gerard · CIK 0001577894 · Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 137,258

F1 · shares: Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the reporting person upon settlement of 7,612 restricted stock units that were awarded in lieu of cash compensation that would otherwise have been owed to the reporting person. No shares were sold by the reporting person or VolitionRx in such transaction.

Read SEC document
October 04, 2025 Filed Oct 7, 2025 20:05 UTC VOLITIONRX LTD VNRX · Entity 8241 Tax withholdingCommon Stock 4,620 $0.65 $2,993.76
Disclosure

SEC source: 0001477932-25-007404 · form4.xml · nonDerivative · entry 1

Rootsaert Rodney Gerard · CIK 0001577894 · Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 140,455

F1 · shares: Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the reporting person upon settlement of 11,000 restricted stock units. No shares were sold by the reporting person or VolitionRx in such transaction.

Read SEC document
September 28, 2025 Filed Sep 30, 2025 20:02 UTC VOLITIONRX LTD VNRX · Entity 8241 Tax withholdingCommon Stock 4,158 $0.61 $2,515.59
Disclosure

SEC source: 0001477932-25-007233 · form4.xml · nonDerivative · entry 1

Rootsaert Rodney Gerard · CIK 0001577894 · Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 145,075

F1 · shares: Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the reporting person upon settlement of 9,900 restricted stock units. No shares were sold by the reporting person or VolitionRx in such transaction.

Read SEC document
August 15, 2025 Filed Aug 19, 2025 20:06 UTC VOLITIONRX LTD VNRX · Entity 8241 GrantCommon Stock 15,223 $0.00 $0.00
Disclosure

SEC source: 0001477932-25-006101 · form4.xml · nonDerivative · entry 1

Rootsaert Rodney Gerard · CIK 0001577894 · Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 149,233

F1 · shares: On August 15, 2025, the reporting person was awarded 15,223 restricted stock units ("RSUs") under the Issuer's 2015 Stock Incentive Plan in lieu of cash compensation that would otherwise have been owed to the reporting person. The RSUs will be earned in six approximately equal monthly installments commencing on September 1, 2025. Once earned, they will remain subject to additional time-based vesting in two installments of 7,612 units and 7,611 units on each of November 1, 2025 and February 1, 2026, respectively, and are generally subject to continued service by the reporting person throughout each applicable earning and vesting date. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have been earned and vested as of the applicable vesting date.

Read SEC document
August 01, 2025 Filed Aug 5, 2025 20:01 UTC VOLITIONRX LTD VNRX · Entity 8241 Tax withholdingCommon Stock 4,279 $0.64 $2,738.56
Disclosure

SEC source: 0001477932-25-005469 · form4.xml · nonDerivative · entry 1

Rootsaert Rodney Gerard · CIK 0001577894 · Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 134,010

F1 · shares: Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the reporting person upon settlement of 10,190 restricted stock units that were awarded in lieu of cash compensation that would otherwise have been owed to the reporting person. No shares were sold by the reporting person or VolitionRx in such transaction.

Read SEC document
July 01, 2025 Filed Jul 3, 2025 17:05 UTC VOLITIONRX LTD VNRX · Entity 8241 Tax withholdingCommon Stock 3,066 $0.77 $2,354.38
Disclosure

SEC source: 0001477932-25-004916 · form4.xml · nonDerivative · entry 1

Rootsaert Rodney Gerard · CIK 0001577894 · Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 138,289

F1 · shares: Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the reporting person upon settlement of 7,302 restricted stock units that were awarded in lieu of cash compensation that would otherwise have been owed to the reporting person. No shares were sold by the reporting person or VolitionRx in such transaction.

Read SEC document
June 01, 2025 Filed Jun 3, 2025 20:06 UTC VOLITIONRX LTD VNRX · Entity 8241 Tax withholdingCommon Stock 6,408 $0.50 $3,223.22
Disclosure

SEC source: 0001477932-25-004370 · form4.xml · nonDerivative · entry 2

Rootsaert Rodney Gerard · CIK 0001577894 · Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 141,355

F2 · shares: Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the reporting person upon settlement of 15,258 restricted stock units that were awarded in lieu of cash compensation that would otherwise have been owed to the reporting person. No shares were sold by the reporting person or VolitionRx in such transaction.

Read SEC document
June 01, 2025 Filed Jun 3, 2025 20:06 UTC VOLITIONRX LTD VNRX · Entity 8241 GrantCommon Stock 10,190 $0.00 $0.00
Disclosure

SEC source: 0001477932-25-004370 · form4.xml · nonDerivative · entry 1

Rootsaert Rodney Gerard · CIK 0001577894 · Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 147,763

F1 · shares: On June 1, 2025, the reporting person was awarded 10,190 restricted stock units ("RSUs") under the Issuer's 2015 Stock Incentive Plan in lieu of cash compensation that would otherwise have been owed to the reporting person. The RSUs partially vest in three installments of 3,397 units, 3,397 units, and 3,396 units on each of June 1, 2025, July 1, 2025 and August 1, 2025, respectively, are also subject to further time-based vesting in a single installment on August 1, 2025, and are generally subject to continued service throughout each applicable vesting date. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested.

Read SEC document
May 01, 2025 Filed May 5, 2025 20:05 UTC VOLITIONRX LTD VNRX · Entity 8241 Tax withholdingCommon Stock 5,453 $0.49 $2,658.34
Disclosure

SEC source: 0001477932-25-003318 · form4.xml · nonDerivative · entry 1

Rootsaert Rodney Gerard · CIK 0001577894 · Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 137,573

F1 · shares: Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the reporting person upon settlement of 12,984 restricted stock units that were awarded in lieu of cash compensation that would otherwise have been owed to the reporting person. No shares were sold by the reporting person or VolitionRx in such transaction.

Read SEC document
March 01, 2025 Filed Mar 4, 2025 21:03 UTC VOLITIONRX LTD VNRX · Entity 8241 GrantCommon Stock 7,908 $0.00 $0.00
Disclosure

SEC source: 0001477932-25-001466 · form4.xml · nonDerivative · entry 1

Rootsaert Rodney Gerard · CIK 0001577894 · Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 143,026

F1 · shares: On March 1, 2025, the reporting person was awarded 7,908 restricted stock units ("RSUs") under the Issuer's 2024 Stock Incentive Plan in lieu of cash compensation that would otherwise have been owed to the reporting person. The RSUs partially vest in three equal installments of 2,636 units on each of March 1, 2025, April 1, 2025 and May 1, 2025, respectively, are also subject to further time-based vesting in a single installment on March 1, 2026, and are generally subject to continued service throughout each applicable vesting date. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested.

Read SEC document
January 29, 2025 Filed Jan 31, 2025 21:05 UTC VOLITIONRX LTD VNRX · Entity 8241 GrantStock Option (Right to Buy) · Derivative 50,000 Not disclosed Strike: $3.25 Not disclosed
Disclosure

SEC source: 0001477932-25-000611 · form4.xml · derivative · entry 2

Rootsaert Rodney Gerard · CIK 0001577894 · Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2029-02-11

F1 · kind: The reported transaction involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on February 11, 2019, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on February 11, 2029 (ten years from the original date of grant).

F1 · price: The reported transaction involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on February 11, 2019, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on February 11, 2029 (ten years from the original date of grant).

Read SEC document
January 29, 2025 Filed Jan 31, 2025 21:05 UTC VOLITIONRX LTD VNRX · Entity 8241 Disposition to issuerStock Option (Right to Buy) · Derivative 50,000 Not disclosed Strike: $3.25 Not disclosed
Disclosure

SEC source: 0001477932-25-000611 · form4.xml · derivative · entry 1

Rootsaert Rodney Gerard · CIK 0001577894 · Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 50,000 shares

Expires 2025-02-11

F1 · kind: The reported transaction involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on February 11, 2019, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on February 11, 2029 (ten years from the original date of grant).

F1 · price: The reported transaction involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on February 11, 2019, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on February 11, 2029 (ten years from the original date of grant).

Read SEC document
December 01, 2024 Filed Dec 3, 2024 21:02 UTC VOLITIONRX LTD VNRX · Entity 8241 GrantCommon Stock 7,302 $0.00 $0.00
Disclosure

SEC source: 0001477932-24-007810 · form4.xml · nonDerivative · entry 1

Rootsaert Rodney Gerard · CIK 0001577894 · Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 135,118

F1 · shares: On December 1, 2024, the reporting person was awarded 7,302 restricted stock units ("RSUs") under the Issuer's 2015 Stock Incentive Plan in lieu of cash compensation that would otherwise have been owed to the reporting person. The RSUs partially vest in three equal installments of 2,434 units on each of December 1, 2024, January 1, 2025 and February 1, 2025, respectively, are also subject to further time-based vesting in a single installment on July 1, 2025, and are generally subject to continued service throughout each applicable vesting date. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested.

Read SEC document
October 04, 2024 Filed Oct 8, 2024 20:01 UTC VOLITIONRX LTD VNRX · Entity 8241 Tax withholdingCommon Stock 4,620 $0.88 $4,079.46
Disclosure

SEC source: 0001477932-24-006284 · form4.xml · nonDerivative · entry 1

Rootsaert Rodney Gerard · CIK 0001577894 · Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 127,816

F1 · shares: Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the reporting person upon settlement of 11,000 restricted stock units. No shares were sold by the reporting person or VolitionRx in such transaction.

Read SEC document
September 28, 2024 Filed Oct 1, 2024 20:05 UTC VOLITIONRX LTD VNRX · Entity 8241 Tax withholdingCommon Stock 4,158 $0.58 $2,403.32
Disclosure

SEC source: 0001477932-24-006099 · form4.xml · nonDerivative · entry 1

Rootsaert Rodney Gerard · CIK 0001577894 · Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 132,436

F1 · shares: Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the reporting person upon settlement of 9,900 restricted stock units. No shares were sold by the reporting person or VolitionRx in such transaction.

Read SEC document
September 01, 2024 Filed Sep 4, 2024 20:02 UTC VOLITIONRX LTD VNRX · Entity 8241 GrantCommon Stock 15,258 $0.00 $0.00
Disclosure

SEC source: 0001477932-24-005496 · form4.xml · nonDerivative · entry 1

Rootsaert Rodney Gerard · CIK 0001577894 · Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 136,594

F1 · shares: On September 1, 2024, the reporting person was awarded 15,258 restricted stock units ("RSUs") under the Issuer's 2015 Stock Incentive Plan in lieu of cash compensation that would otherwise have been owed to the reporting person. The RSUs partially vest in three equal installments of 5,086 units on each of September 1, 2024, October 1, 2024 and November 1, 2024, respectively, are also subject to further time-based vesting in a single installment on June 1, 2025, and are generally subject to continued service throughout each applicable vesting date. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested.

Read SEC document
August 15, 2024 Filed Aug 16, 2024 20:05 UTC VOLITIONRX LTD VNRX · Entity 8241 GrantCommon Stock 11,000 $0.00 $0.00
Disclosure

SEC source: 0001477932-24-005027 · form4.xml · nonDerivative · entry 1

Rootsaert Rodney Gerard · CIK 0001577894 · Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 121,336

F1 · shares: On Sept 28, 2023, the reporting person was awarded 44,000 restricted stock units ("RSUs") under the Issuer's 2015 Stock Incentive Plan, subject to vesting upon the achievement of certain corporate performance goals on or prior to Dec 31, 2023 and June 30, 2024 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 11,000 RSUs vesting. The RSUs are further subject to a 3-year time-based vesting schedule, vesting in three installments of 3,666 units, 3,667 units, and 3,667 units on each of Sept 28, 2024, 2025 and 2026, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested. As reported in Jan 2024, the rights with respect to 18,700 RSUs subject to the award previously vested and remain subject to time-based vesting. The rights with respect to the remaining 14,300 RSUs did not vest and were cancelled on August 15, 2024.

Read SEC document
June 01, 2024 Filed Jun 4, 2024 20:05 UTC VOLITIONRX LTD VNRX · Entity 8241 GrantCommon Stock 12,984 $0.00 $0.00
Disclosure

SEC source: 0001477932-24-003477 · form4.xml · nonDerivative · entry 1

Rootsaert Rodney Gerard · CIK 0001577894 · Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 110,336

F1 · shares: On June 1, 2024, the reporting person was awarded 12,984 restricted stock units ("RSUs") under the Issuer's 2015 Stock Incentive Plan in lieu of cash compensation that would otherwise have been owed to the reporting person. The RSUs partially vest in three equal installments of 4,328 units on each of June 1, 2024, July 1, 2024 and August 1, 2024, respectively, are also subject to further time-based vesting in a single installment on May 1, 2025, and are generally subject to continued service throughout each applicable vesting date. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested.

Read SEC document
January 24, 2024 Filed Jan 26, 2024 21:03 UTC VOLITIONRX LTD VNRX · Entity 8241 GrantCommon Stock 18,700 $0.00 $0.00
Disclosure

SEC source: 0001477932-24-000406 · form4.xml · nonDerivative · entry 1

Rootsaert Rodney Gerard · CIK 0001577894 · Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 97,352

F1 · shares: On September 28, 2023, the reporting person was awarded 44,000 restricted stock units ("RSUs") under the Issuer's 2015 Stock Incentive Plan, subject to vesting upon the achievement of certain corporate performance goals on or prior to December 31, 2023 and June 30, 2024 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 18,700 RSUs vesting. The RSUs are further subject to a 3-year time-based vesting schedule, vesting in three installments of 6,234 units, 6,233 units, and 6,233 units on each of September 28, 2024, September 28, 2025 and September 28, 2026, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested.

Read SEC document
December 13, 2023 Filed Dec 14, 2023 14:11 UTC VOLITIONRX LTD VNRX · Entity 8241 PurchaseCommon Stock 10,000 $0.60 $6,000.00
Disclosure

SEC source: 0001477932-23-009129 · form4.xml · nonDerivative · entry 1

Rootsaert Rodney Gerard · CIK 0001577894 · Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 78,652

Read SEC document
August 03, 2023 Filed Aug 7, 2023 20:05 UTC VOLITIONRX LTD VNRX · Entity 8241 Tax withholdingCommon Stock 4,850 $1.30 $6,305.00
Disclosure

SEC source: 0001477932-23-005790 · form4.xml · nonDerivative · entry 1

Rootsaert Rodney Gerard · CIK 0001577894 · Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 68,652

F1 · shares: Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation to satisfy the tax withholding obligations of the reporting person upon settlement of 10,052 restricted stock units. No shares were sold by the reporting person or VolitionRx in such transaction.

Read SEC document
July 05, 2023 Filed Jul 7, 2023 20:02 UTC VOLITIONRX LTD VNRX · Entity 8241 GrantCommon Stock 14,850 $0.00 $0.00
Disclosure

SEC source: 0001477932-23-005116 · form4.xml · nonDerivative · entry 1

Rootsaert Rodney Gerard · CIK 0001577894 · Secretary

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 73,502

F1 · shares: On October 4, 2022, the reporting person was awarded 33,000 restricted stock units ("RSUs") under the Issuer's 2015 Stock Incentive Plan, subject to vesting upon the achievement of certain corporate performance goals on or prior to December 31, 2022 and June 30, 2023 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 14,850 RSUs vesting. The RSUs are further subject to a 3-year time-based vesting schedule, vesting in three equal installments of 4,950 units on each of October 4, 2023, October 4, 2024 and October 4, 2025, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of RSUs that have vested. As reported in October 2022 and January 2023 respectively, the rights with respect to 5,775 RSUs and 12,375 RSUs subject to the award previously vested and remain subject to time-based vesting.

Read SEC document
January 12, 2023 Filed Jan 13, 2023 21:05 UTC VOLITIONRX LTD VNRX · Entity 8241 GrantCommon Stock 12,375 $0.00 $0.00
Disclosure

SEC source: 0001477932-23-000278 · form4.xml · nonDerivative · entry 1

Rootsaert Rodney Gerard · CIK 0001577894 · Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 58,652

F1 · shares: On October 4, 2022, the reporting person was awarded 33,000 restricted stock units under the Issuer's 2015 Stock Incentive Plan, subject to vesting upon the achievement of certain corporate performance goals on or prior to December 31, 2022 and June 30, 2023 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 12,375 restricted stock units vesting. The restricted stock units are further subject to a 3-year time-based vesting schedule, vesting in three equal installments of 4,125 units on each of October 4, 2023, October 4, 2024 and October 4, 2025, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. As reported in October 2022, the rights with respect to 5,775 restricted stock units subject to the award previously vested and remain subject to time-based vesting.

Read SEC document
October 13, 2022 Filed Oct 14, 2022 20:06 UTC VOLITIONRX LTD VNRX · Entity 8241 GrantCommon Stock 5,775 $0.00 $0.00
Disclosure

SEC source: 0001477932-22-007700 · form4.xml · nonDerivative · entry 1

Rootsaert Rodney Gerard · CIK 0001577894 · Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,277

F1 · shares: On October 4, 2022, the reporting person was awarded 33,000 restricted stock units under the Issuer's 2015 Stock Incentive Plan, subject to vesting upon the achievement of certain corporate performance goals on or prior to December 31, 2022 and June 30, 2023 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 5,775 restricted stock units vesting. The restricted stock units are further subject to a 3-year time-based vesting schedule, vesting in three equal installments of 1,925 units on each of October 4, 2023, October 4, 2024 and October 4, 2025, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

Read SEC document
June 23, 2022 Filed Jun 24, 2022 20:01 UTC VOLITIONRX LTD VNRX · Entity 8241 GrantStock Option (Right to Buy) · Derivative 24,083 $0.00 Strike: $3.40 $0.00
Disclosure

SEC source: 0001477932-22-004655 · form4.xml · derivative · entry 3

Rootsaert Rodney Gerard · CIK 0001577894 · Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,050

Underlying: Common Stock · 24,083 shares

Expires 2031-08-03

F3 · derivative.exercise_date: On August 3, 2021, the reporting person was granted an option to purchase 37,050 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 24,083 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two installments of 12,042 shares and 12,041 shares on each of August 3, 2022 and August 3, 2023, respectively. As reported in April 2022, the rights with respect to the remaining 12,967 shares subject to the award previously vested and remain subject to time-based vesting.

F3 · balance_after: On August 3, 2021, the reporting person was granted an option to purchase 37,050 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 24,083 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two installments of 12,042 shares and 12,041 shares on each of August 3, 2022 and August 3, 2023, respectively. As reported in April 2022, the rights with respect to the remaining 12,967 shares subject to the award previously vested and remain subject to time-based vesting.

Read SEC document
June 23, 2022 Filed Jun 24, 2022 20:01 UTC VOLITIONRX LTD VNRX · Entity 8241 GrantCommon Stock 13,068 $0.00 $0.00
Disclosure

SEC source: 0001477932-22-004655 · form4.xml · nonDerivative · entry 1

Rootsaert Rodney Gerard · CIK 0001577894 · Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,502

F1 · shares: On August 3, 2021, the reporting person was awarded 20,104 restricted stock units, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 13,068 restricted stock units vesting. The restricted stock units are further subject to a 2-year time-based vesting schedule, vesting in two equal installments of 6,534 units on each of August 3, 2022 and August 3, 2023, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested. As reported in April 2022, the rights with respect to the remaining 7,036 restricted stock units subject to the award previously vested and remain subject to time-based vesting.

Read SEC document
April 07, 2022 Filed Apr 8, 2022 20:02 UTC VOLITIONRX LTD VNRX · Entity 8241 GrantStock Option (Right to Buy) · Derivative 12,967 $0.00 Strike: $3.40 $0.00
Disclosure

SEC source: 0001477932-22-002179 · form4.xml · derivative · entry 3

Rootsaert Rodney Gerard · CIK 0001577894 · Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,967

Underlying: Common Stock · 12,967 shares

Expires 2031-08-03

F3 · derivative.exercise_date: On August 3, 2021, the reporting person was granted an option to purchase 37,050 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 12,967 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two installments of 6,483 shares and 6,484 shares on each of August 3, 2022 and August 3, 2023, respectively.

F3 · balance_after: On August 3, 2021, the reporting person was granted an option to purchase 37,050 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 12,967 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two installments of 6,483 shares and 6,484 shares on each of August 3, 2022 and August 3, 2023, respectively.

Read SEC document
April 07, 2022 Filed Apr 8, 2022 20:02 UTC VOLITIONRX LTD VNRX · Entity 8241 GrantCommon Stock 7,036 $0.00 $0.00
Disclosure

SEC source: 0001477932-22-002179 · form4.xml · nonDerivative · entry 1

Rootsaert Rodney Gerard · CIK 0001577894 · Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,434

F1 · shares: On August 3, 2021, the reporting person was awarded 20,104 restricted stock units, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 7,036 restricted stock units vesting. The restricted stock units are further subject to a 2-year time-based vesting schedule, vesting in two equal installments of 3,518 units on each of August 3, 2022 and August 3, 2023, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

Read SEC document
November 03, 2021 Filed Nov 5, 2021 20:05 UTC VOLITIONRX LTD VNRX · Entity 8241 GrantStock Option (Right to Buy) · Derivative 50,000 Not disclosed Strike: $4.00 Not disclosed
Disclosure

SEC source: 0001477932-21-007862 · form4.xml · derivative · entry 4

Rootsaert Rodney Gerard · CIK 0001577894 · Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2028-01-23

F2 · kind: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on January 23, 2018, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on January 23, 2028 (ten years from the original date of grant).

F2 · price: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on January 23, 2018, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on January 23, 2028 (ten years from the original date of grant).

Read SEC document
November 03, 2021 Filed Nov 5, 2021 20:05 UTC VOLITIONRX LTD VNRX · Entity 8241 Disposition to issuerStock Option (Right to Buy) · Derivative 50,000 Not disclosed Strike: $4.00 Not disclosed
Disclosure

SEC source: 0001477932-21-007862 · form4.xml · derivative · entry 3

Rootsaert Rodney Gerard · CIK 0001577894 · Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 50,000 shares

Expires 2024-01-23

F2 · kind: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on January 23, 2018, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on January 23, 2028 (ten years from the original date of grant).

F2 · price: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on January 23, 2018, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on January 23, 2028 (ten years from the original date of grant).

Read SEC document
November 03, 2021 Filed Nov 5, 2021 20:05 UTC VOLITIONRX LTD VNRX · Entity 8241 GrantStock Option (Right to Buy) · Derivative 65,000 Not disclosed Strike: $4.00 Not disclosed
Disclosure

SEC source: 0001477932-21-007862 · form4.xml · derivative · entry 2

Rootsaert Rodney Gerard · CIK 0001577894 · Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 65,000

Underlying: Common Stock · 65,000 shares

Expires 2026-04-15

F1 · kind: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on April 15, 2016, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on April 15, 2026 (ten years from the original date of grant).

F1 · price: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on April 15, 2016, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on April 15, 2026 (ten years from the original date of grant).

Read SEC document
November 03, 2021 Filed Nov 5, 2021 20:05 UTC VOLITIONRX LTD VNRX · Entity 8241 Disposition to issuerStock Option (Right to Buy) · Derivative 65,000 Not disclosed Strike: $4.00 Not disclosed
Disclosure

SEC source: 0001477932-21-007862 · form4.xml · derivative · entry 1

Rootsaert Rodney Gerard · CIK 0001577894 · Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 65,000 shares

Expires 2022-04-15

F1 · kind: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on April 15, 2016, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on April 15, 2026 (ten years from the original date of grant).

F1 · price: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on April 15, 2016, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on April 15, 2026 (ten years from the original date of grant).

Read SEC document
September 21, 2021 Filed Sep 23, 2021 20:44 UTC VOLITIONRX LTD VNRX · Entity 8241 GrantOption (Right to Buy) · Derivative 55,000 $0.00 Strike: $3.60 $0.00
Disclosure

SEC source: 0001477932-21-006596 · form4.xml · derivative · entry 4

Rootsaert Rodney Gerard · CIK 0001577894 · Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,000

Underlying: Common Stock · 55,000 shares

Expires 2030-04-13

F2 · kind: The reported transactions involved a cancellation and reissuance of outstanding options upon agreement of the reporting person. The "old" options were originally granted on April 13, 2020 and vested in full at 12 months from the date of grant, and were exercisable until April 13, 2026. The "replacement" options are fully-vested on the date of grant and have an expiration date of April 13, 2030.

Read SEC document
September 21, 2021 Filed Sep 23, 2021 20:44 UTC VOLITIONRX LTD VNRX · Entity 8241 GrantOption (Right to Buy) · Derivative 60,000 $0.00 Strike: $5.00 $0.00
Disclosure

SEC source: 0001477932-21-006596 · form4.xml · derivative · entry 2

Rootsaert Rodney Gerard · CIK 0001577894 · Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,000

Underlying: Common Stock · 60,000 shares

Expires 2027-03-30

F1 · kind: The reported transactions involved a cancellation and reissuance of outstanding options upon agreement of the reporting person. The "old" options were originally granted on December 16, 2019, vested in full on the date of grant, and were exercisable until March 30, 2023. The "replacement" options are fully-vested on the date of grant and have an expiration date of March 30, 2027.

Read SEC document
July 14, 2021 Filed Jul 16, 2021 21:05 UTC VOLITIONRX LTD VNRX · Entity 8241 GrantStock Option (Right to Buy) · Derivative 35,000 Not disclosed Strike: $4.00 Not disclosed
Disclosure

SEC source: 0001078782-21-000680 · primary_doc.xml · derivative · entry 2

Rootsaert Rodney Gerard · CIK 0001577894 · Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,000

Underlying: Common Stock · 35,000 shares

Expires 2025-07-23

F1 · kind: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on July 23, 2015, vested in full and were exercisable at 6 months from the date of grant, and as amended were exercisable for five years and six months from the date first exercisable. The "replacement" options are fully-vested and expire on July 23, 2025 (ten years from the date of grant).

F1 · price: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on July 23, 2015, vested in full and were exercisable at 6 months from the date of grant, and as amended were exercisable for five years and six months from the date first exercisable. The "replacement" options are fully-vested and expire on July 23, 2025 (ten years from the date of grant).

Read SEC document
July 14, 2021 Filed Jul 16, 2021 21:05 UTC VOLITIONRX LTD VNRX · Entity 8241 Disposition to issuerStock Option (Right to Buy) · Derivative 35,000 Not disclosed Strike: $4.00 Not disclosed
Disclosure

SEC source: 0001078782-21-000680 · primary_doc.xml · derivative · entry 1

Rootsaert Rodney Gerard · CIK 0001577894 · Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 35,000 shares

Expires 2021-07-23

F1 · kind: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on July 23, 2015, vested in full and were exercisable at 6 months from the date of grant, and as amended were exercisable for five years and six months from the date first exercisable. The "replacement" options are fully-vested and expire on July 23, 2025 (ten years from the date of grant).

F1 · price: The reported transactions involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on July 23, 2015, vested in full and were exercisable at 6 months from the date of grant, and as amended were exercisable for five years and six months from the date first exercisable. The "replacement" options are fully-vested and expire on July 23, 2025 (ten years from the date of grant).

Read SEC document
July 21, 2020 Filed Jul 23, 2020 20:23 UTC VOLITIONRX LTD VNRX · Entity 8241 Exercise / conversionStock Option (Right to Buy) · Derivative 30,000 $0.00 Strike: $3.00 $0.00
Disclosure

SEC source: 0001078782-20-000558 · primary_doc.xml · derivative · entry 7

Rootsaert Rodney Gerard · CIK 0001577894 · Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 30,000 shares

Expires 2020-08-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
July 21, 2020 Filed Jul 23, 2020 20:23 UTC VOLITIONRX LTD VNRX · Entity 8241 Exercise / conversionStock Option (Right to Buy) · Derivative 30,000 $0.00 Strike: $2.50 $0.00
Disclosure

SEC source: 0001078782-20-000558 · primary_doc.xml · derivative · entry 6

Rootsaert Rodney Gerard · CIK 0001577894 · Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 30,000 shares

Expires 2020-08-18

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
July 21, 2020 Filed Jul 23, 2020 20:23 UTC VOLITIONRX LTD VNRX · Entity 8241 Tax withholdingCommon Stock 25,816 $3.95 $101,973.20
Disclosure

SEC source: 0001078782-20-000558 · primary_doc.xml · nonDerivative · entry 4

Rootsaert Rodney Gerard · CIK 0001577894 · Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,398

F1 · shares: Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation as payment of the exercise price in a cashless exercise and to satisfy the tax withholding obligations of the Reporting Person. No shares were sold by the Reporting Person or VolitionRx in such cashless exercise transaction.

Read SEC document
July 21, 2020 Filed Jul 23, 2020 20:23 UTC VOLITIONRX LTD VNRX · Entity 8241 Exercise / conversionCommon Stock 30,000 $3.00 $90,000.00
Disclosure

SEC source: 0001078782-20-000558 · primary_doc.xml · nonDerivative · entry 3

Rootsaert Rodney Gerard · CIK 0001577894 · Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,214

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
July 21, 2020 Filed Jul 23, 2020 20:23 UTC VOLITIONRX LTD VNRX · Entity 8241 Tax withholdingCommon Stock 23,614 $3.95 $93,275.30
Disclosure

SEC source: 0001078782-20-000558 · primary_doc.xml · nonDerivative · entry 2

Rootsaert Rodney Gerard · CIK 0001577894 · Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,214

F1 · shares: Represents the aggregate number of shares of common stock retained by VolitionRx for cancellation as payment of the exercise price in a cashless exercise and to satisfy the tax withholding obligations of the Reporting Person. No shares were sold by the Reporting Person or VolitionRx in such cashless exercise transaction.

Read SEC document
July 21, 2020 Filed Jul 23, 2020 20:23 UTC VOLITIONRX LTD VNRX · Entity 8241 Exercise / conversionCommon Stock 30,000 $2.50 $75,000.00
Disclosure

SEC source: 0001078782-20-000558 · primary_doc.xml · nonDerivative · entry 1

Rootsaert Rodney Gerard · CIK 0001577894 · Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,828

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
April 13, 2020 Filed Apr 15, 2020 21:08 UTC VOLITIONRX LTD VNRX · Entity 8241 GrantStock Option (Right to Buy) · Derivative 55,000 $0.00 Strike: $3.60 $0.00
Disclosure

SEC source: 0001078782-20-000265 · primary_doc.xml · derivative · entry 1

Rootsaert Rodney Gerard · CIK 0001577894 · Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,000

Underlying: Common Stock · 55,000 shares

Expires 2026-04-13

F1 · derivative.exercise_date: A total of 55,000 Options were granted on April 13, 2020 under the Company's 2015 Stock Incentive Plan. The Options vest in full twelve months from the date of grant.

Read SEC document
April 13, 2020 Filed Sep 23, 2021 20:44 UTC VOLITIONRX LTD VNRX · Entity 8241 Disposition to issuerOption (Right to Buy) · Derivative 55,000 $0.00 Strike: $3.60 $0.00
Disclosure

SEC source: 0001477932-21-006596 · form4.xml · derivative · entry 3

Rootsaert Rodney Gerard · CIK 0001577894 · Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 55,000 shares

Expires 2026-04-13

F2 · kind: The reported transactions involved a cancellation and reissuance of outstanding options upon agreement of the reporting person. The "old" options were originally granted on April 13, 2020 and vested in full at 12 months from the date of grant, and were exercisable until April 13, 2026. The "replacement" options are fully-vested on the date of grant and have an expiration date of April 13, 2030.

Read SEC document
December 16, 2019 Filed Dec 18, 2019 16:49 UTC VOLITIONRX LTD VNRX · Entity 8241 GrantOption (Right to Buy) · Derivative 60,000 $0.00 Strike: $5.00 $0.00
Disclosure

SEC source: 0001078782-19-000926 · primary_doc.xml · derivative · entry 2

Rootsaert Rodney Gerard · CIK 0001577894 · Secretary

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,000

Underlying: Common Stock · 60,000 shares

Expires 2023-03-30

F1 · kind: The reported transactions involved a cancellation and reissuance of a portion of outstanding options upon agreement of the reporting person. The "old" options were originally granted on March 30, 2017 and vested in full at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested on the date of grant and have the same expiration date and exercise price as the "old" options.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.